Date

Time

Title

Speaker

9 May (Tue)

13:30~14:00

Registration Check-in

14:00~14:10

Opening Remarks

President of KIRAMS

Modulator: Ilhan Lim

14:10~14:50

Current trends of Targeted Alpha Therapy

Alfred Morgenstern

(Joint Research Centre of the European Commission)

14:50~15:30

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (on line)

Mike Sathekge

 (University of Pretoria and Steve Biko Academic Hospital, South Africa)

15:30~15:50

Coffee Break

15:50~16:30

Targeted Alpha Therapy using Astatine-211

Tadashi Watabe

(Osaka University, Japan)

Modulator: Kyo Chul Lee

16:30~16:45

Production of At-211 using KIRAMS MC50 Cyclotron

Seyoung Oh

(KIRAMS, Korea)

16:45~17:00

Introduction of radiopharmaceuticals GMP in KIRAMS

Boeun Lee

(KIRAMS, Korea)

17:00~17:15

Introduction of radiopharmaceuticals GLP in KIRAMS

Inki Lee

(KIRAMS, Korea)

17:15~17:35

Clinical Targeted alpha therapy in KIRAMS

Ilhan Lim

(KIRAMS, Korea)

17:35~17:50

Q&A and Discussion

17:50~18:00

Closing Remarks

Kyeong Min Kim

(KIRAMS, Korea)